Akira Kameda
About
In The Last Decade
Akira Kameda
17 papers receiving 715 citations
Peers
Comparison fields: 5 of 84
- Molecular Biology 370
- Oncology 283
- Orthopedics and Sports Medicine 179
- Nutrition and Dietetics 122
- Genetics 115
Countries citing papers authored by Akira Kameda
This map shows the geographic impact of Akira Kameda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akira Kameda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akira Kameda more than expected).
Fields of papers citing papers by Akira Kameda
This network shows the impact of papers produced by Akira Kameda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akira Kameda. The network helps show where Akira Kameda may publish in the future.
Co-authorship network of co-authors of Akira Kameda
This figure shows the co-authorship network connecting the top 25 collaborators of Akira Kameda. A scholar is included among the top collaborators of Akira Kameda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akira Kameda. Akira Kameda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | [A case of lung cancer in an elderly patient with malignant pleural effusion and pneumothorax treated with carboplatin, pemetrexed, and bevacizumab]. | 0 |
| 2 | [A case of advanced gastric cancer with recurrence-free long survival showing disappearance of distant lymph node metastases by S-1/docetaxel therapy followed by curative resection]. | 1 |
| 3 | 3 | |
| 4 | Docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer. | 5 |
| 5 | [Chemotherapy for patients with non-curative advanced or recurrent gastric cancer in our hospital]. | 2 |
| 6 | [Combination of carboplatin and gemcitabine is a safe and feasible regimen in adjuvant therapy for stage II and IIIA NSCLC]. | 2 |
| 7 | 3 | |
| 8 | 1 | |
| 9 | 0 | |
| 10 | 0 | |
| 11 | 175 | |
| 12 | 1 | |
| 13 | 377 | |
| 14 | 120 | |
| 15 | 8 | |
| 16 | 3 | |
| 17 | 8 | |
| 18 | 10 | |
| 19 | 1 | |
| 20 | 14 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.